Source : https://pubmed.ncbi.nlm.nih.gov/40197620/
A global obesity pandemic, coupled with an increasingly ageing population, is exacerbating the burden of cardiovascular disease. Indeed, clinical and experimental evidence underscores a potential connection between obesity and ageing...
Obesity accelerates cardiovascular aging through shared mechanisms like inflammation and mitochondrial dysfunction; weight reduction and metabolic therapies may counteract these processes, reducing cardiovascular disease risk and improving longevity.
Obesity-related TyG indices, reflecting insulin resistance, were linked to higher risk of retinal arteriosclerosis. Findings highlight how metabolic dysfunction and poor cardiovascular health contribute to early microvascular injury, reinforcing the need for integrated risk assessment.
Source : https://pubmed.ncbi.nlm.nih.gov/41948357/
Insulin resistance due to lipodystrophy syndromes is an uncommon but important cause of diabetes. It is often overlooked due to limited awareness. Standard glucose-lowering therapies often fail to achieve durable...
Lipodystrophy is a rare cause of insulin resistance and early diabetes, often misdiagnosed. Genetic causes like SHORT syndrome should be suspected in lean patients with atypical features and poor response to standard therapies.
Source : https://pubmed.ncbi.nlm.nih.gov/41918976/
The physiological roles of prolactin extend beyond its classical functions in reproductive regulation. Emerging evidence indicates that prolactin is involved in energy homeostasis and may interact pathophysiologically with obesity; this...
Source : https://pubmed.ncbi.nlm.nih.gov/41774188/
The global rise in obesity and depression, two highly prevalent and often comorbid disorders has intensified interest in the gut-brain axis as a shared biological link. Mounting evidence indicates that...
Review links gut dysbiosis to obesity-depression comorbidity via SCFAs, GLP-1, bile acids modulating metabolism, inflammation, mood through gut-brain axis; GLP-1RAs (semaglutide), psychobiotics, FMT offer dual-targeting therapeutic promise.